SCHEMBL6569077

SCHEMBL6569077

CC(=NNC(=O)c1ccc(O)cc1)c1cc(O)ccc1O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.74
MAPT P10636 8/20 0.68
GAA P10253 6/20 0.68
ALDH1A1 P00352 5/20 0.68
RAB9A P51151 5/20 0.68
KDM4E B2RXH2 4/20 0.68
HTT P42858 3/20 0.68
MCL1 Q07820 2/20 0.68
MEN1 O00255 1/20 0.68
PKM P14618 1/20 0.68
KMT2A Q03164 1/20 0.68
SMN1; SMN2 Q16637 1/20 0.68
TDP1 Q9NUW8 1/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
ESRRG P62508 2/20 0.58
POLB P06746 4/20 0.56
NPC1 O15118 3/20 0.56
CASP6 P55212 2/20 0.56
MTOR P42345 2/20 0.55
NPSR1 Q6W5P4 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6569073 1.00 KDM1A (0.74) KDM1AMAPTGAAALDH1A1RAB9A
SCHEMBL6569109 0.91 KDM1A (0.76) KDM1AMAPTGAAALDH1A1RAB9A
SCHEMBL6569104 0.91 KDM1A (0.76) KDM1AMAPTGAAALDH1A1RAB9A
SCHEMBL19283335 0.88 KDM1A (0.74) KDM1AMAPTGAAALDH1A1RAB9A
SCHEMBL19283334 0.88 KDM1A (0.74) KDM1AMAPTGAAALDH1A1RAB9A
SCHEMBL23719208 0.85 KDM1A (1.00) KDM1AMAPTGAAALDH1A1RAB9A
SCHEMBL19283326 0.85 KDM1A (1.00) KDM1AMAPTGAAALDH1A1RAB9A
SCHEMBL14712657 0.85 KDM1A (1.00) KDM1AMAPTGAAALDH1A1RAB9A
SCHEMBL12387921 0.84 MAPT (0.61) KDM1AMAPTGAAALDH1A1RAB9A
SCHEMBL684598 0.84 KDM1A (0.61) KDM1AMAPTGAAALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170246130-A1 4-HYDROXYBENZOHYDARZIDE-A NEW CLASS OF ANGIOGENIC ENZYME THYMIDINE PHOSPHORYLASE INHIBITORS CHOUDHARY MUHAMMAD IQBAL (PK) 2017-08-31 US claimed
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US claimed
US-20170246130-A1 4-HYDROXYBENZOHYDARZIDE-A NEW CLASS OF ANGIOGENIC ENZYME THYMIDINE PHOSPHORYLASE INHIBITORS CHOUDHARY MUHAMMAD IQBAL (PK) 2017-08-31 US disclosed
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US disclosed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP disclosed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110963-A1 Novel hydrazones H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO KDM1A 2684/4885MAPT 3140/4885GAA 588/4885
US-20170246130-A1 4-HYDROXYBENZOHYDARZIDE-A NEW CLASS OF ANGIOGENIC ENZYME THYMIDINE PHOSPHORYLASE INHIBITORS TYMP, DPYD, FLT4 KDM1A 732/4885MAPT 4301/4885GAA 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.